RG
FDMT icon

Redmile Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Redmile Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-112,168
Closed -$416K – 43
2025
Q2 		$416K Sell
112,168
-885,067
-89% -$3.11M 0.04% 47
2025
Q1 		$3.22M Sell
997,235
-199,675
-17% -$941K 0.3% 44
2024
Q4 		$6.67M Sell
1,196,910
-65,180
-5% -$512K 0.46% 41
2024
Q3 		$13.6M Buy
1,262,090
+188,655
+18% +$3.13M 0.8% 33
2024
Q2 		$22.5M Sell
1,073,435
-187,992
-15% -$4.72M 1.36% 29
2024
Q1 		$40.2M Buy
+1,261,427
New +$32.2M 1.48% 25

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Redmile Group's FDMT Position: Q3 2025 in Review

Redmile Group sold out of 4D Molecular Therapeutics (FDMT) in Q3 2025, closing a stake of 112,168 shares — an estimated $416K sold.

Redmile Group first reported a position in FDMT in Q1 2024 and held it in 6 quarters. The position peaked at $40.2M in Q1 2024. 134 funds tracked by Wall St. Rank hold FDMT as of Q3 2025.

  • Redmile Group reported no remaining 4D Molecular Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Redmile Group sold 112,168 4D Molecular Therapeutics shares in Q3 2025, an estimated $416K.
  • Redmile Group first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 6 quarters.
  • Redmile Group's 4D Molecular Therapeutics position peaked at $40.2M in Q1 2024.
  • 134 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2025.

Based on Redmile Group's 13F filing for Q3 2025, filed 14 Nov 2025.